SMi Group has introduced its Peptides conference to the its schedule this June in London

1. O FO 3 B
R R 1 O
FO BO £3 ST OK
R OK 00 MA B
£1 B D R Y
00 Y IS CH
DI 30 CO
SC TH UN
O AP T
UN R
T IL
SMi present their inaugural conference on…
30TH JUNE
1ST JULY
PEPTIDES
Assessing Analytical Developments, Peptide Formulation
and Delivery to Enhance Therapeutic Developments
2014
Marriott Regents Park Hotel, London, UK
CHAIRS FOR 2014:
Joel Richard,
Vice President,
Peptides,
IPSEN Inc.
Yvonne Angell,
Director of
Peptide and
Protein Chemistry,
IPSEN Inc.
KEY SPEAKERS INCLUDE:
• Thomas Vorherr, Director Peptide Discovery, Novartis
Pharma AG
• Christian Luber, Senior Scientist, Novo Nordisk
• Nuno Madeira do O, Associate Scientist II, Formulation
Sciences, MedImmune
• David Price, Senior Director, Pfizer
• Ved Srivastava, Head, Peptide Chemistry,
GlaxoSmithKline
• Dinesh V. Patel, President and CEO, Protagonist
Therapeutics Inc.
• Annette Friebe, Head, Late Discovery, Nexigen GmbH
• Christophe Bonny, CSO, Bicycle Therapeutics
BUSINESS BENEFITS FOR 2014:
• Gain insight into engineering peptide therapeutics
for optimal drug delivery
• Hear what analytical methods can be utilised to
enhance product design
• Strengthen your knowledge on strategies to
enhance the development of novel peptides
• Assess new formulations and routes for
administration of peptides
PLUS AN INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 2nd July 2014, Marriott Regents Park Hotel, London, UK
Extending the Half-Life of Peptides
Workshop Leader:
Yvonne Angell, Director of Peptide and Protein Chemistry, IPSEN Inc.
8.30am – 12.30pm
www.peptidesevent.com
BOOK BY 31ST MARCH AND SAVE £300 / BOOK BY 30TH APRIL AND SAVE £100
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
@SMIpharm

2. Peptides
www.peptide
Day One | Monday 30th June 2014
8.30
Registration & Coffee
9.00
Chairman's Opening Remarks
Yvonne Angell, Director of Peptide and Protein Chemistry,
IPSEN Inc.
1.30
Responsive delivery systems for extended release of
peptides and proteins
PEPTIDE FORMUALTION AND DELIVERY
9.10
• Strategies for solubilisation and stability enhancement
• Tuning release rates
• Manufacturing and device selection
Fredrik Tiberg, President and CEO, Camurus AB
PART
ONE
OPENING ADDRESS
Physical and Conformational Stability:
Understanding, Characterising and Formulating Peptides
• Introduction
• Formulation challenges and characterisation
techniques
• Case Study
• Concluding remarks
Nuno Madeira do O, Associate Scientist II,
Formulation Sciences, MedImmune
SPOTLIGHT PRESENTATION
2.10
Challenges for the design of permeable
therapeutic peptides
• Peptide synthesis
• Intracellular transport
• Oral bioavailability
Thomas Vorherr, Director Peptide Discovery,
Novartis Pharma AG
2.50
9.10
Case study: Development of cell-permeable
therapeutic peptides targeting Wnt signalling in cancer
• Identification of functional peptides utilizing a cellular yeast
screening platform
• Development of cell-permeable peptides with anti-tumour
activity in vitro and in vivo
• Pharmacology of the lead candidate
Annette Friebe, Head, Late Discovery, Nexigen GmbH
Afternoon Tea
3.20
Novel Hepcidin Agonists
• Hepcidin is a natural peptide hormone that regulates iron
homeostasis. Hepcidin deficiency is associated with iron
overload disorders such as beta-thalassemia and juvenile
hemochromatosis.
• Hepcidin is structurally complex (25-mer with 4-disulfidecross linked beta-hairpin), difficult to synthesize, and prone
10.30
11.00
Morning Coffee
to aggregation. A hepcidin agonist with suitable drug-like
THE DEVELOPMENT OF NEW PEPTIDE DRUGS
11.40
12.20
properties is highly desired.
KEYNOTE ADDRESS
Oral Bioavailability of Peptides
• Strategic way to bring new products to market
that are more efficient and have higher efficacy
• Linking PK and bio-distribution of peptide
therapeutics with their pharmacological activity
• Future directions
David Price, Senior Director, Pfizer
• Protagonist has utilized its proprietary VectrixTM technology
platform and ‘scaffold hoping’ to identify novel hepcidin
agonists with equivalent in vivo potency to hepcidin and
superior physiochemical properties.
Gregory T. Bourne, Research Fellow, Protagonist
Therapeutics Inc.
4.00
peptide sequence
• What challenges are being faced for manufacturing products?
Strategies to enhance the development of novel peptide
drugs
• Enhancing high specificity, potency and low toxicity of
novel therapeutics
• Improving the viability of oral delivery for peptides
• Assessing the distinct advantages peptides have
over small molecules
Yvonne Angell, Director of Peptide and Protein
Chemistry, IPSEN Inc.
Networking Lunch
Manufacturability – Understanding the criteria to form a
•Understanding the characterisation of peptides to
understand their risk profile, e.g. solubility
•Assessing how the product could behave in large scale
manufacturing
Annette Friebe, Head, Late Discovery, Nexigen GmbH
David Price, Director, Pfizer
Joel Richard, Vice President, Peptides, IPSEN Inc.
4.40
Chairman’s Closing Remarks and Close of Day One
Register online at: www.peptidesevent.com • Alternatively fax yo
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement
your company’s marketing strategy. Prime networking opportunities exist to entertain, enhance and
expand your client base within the context of an independent discussion specific to your industry.
Should you wish to join the increasing number of companies benefiting from sponsoring
our conferences please call: Alia Malick on +44 (0) 20 7827 6168 or
email: amalick@smi-online.co.uk
Want to know how you can get
involved? Interested in promoting
your services to this market?
Contact Humaira Kaiser, SMi Marketing
on +44 (0) 207 827 6167, or email:
hkaiser@smi-online.co.uk

3. esevent.com
8.30
Registration & Coffee
9.00
Day Two | Tuesday 1st July 2014
Chairman's Opening Remarks
Joel Richard, Vice President, Peptides, IPSEN Inc.
FORMUALTION AND DELIVERY
9.10
BIOPHYSICAL CHARACTERISATION
1.30
Targeting Mitochondria with Cationic Amphipathic Short Peptides
• A novel class of water-soluble tetrapeptides (“SS peptides”)
was recently reported, with the view to protect cells against
PART
TWO
ROS-mediated oxidative stress.
OPENING ADDRESS
Peptide Delivery: Where Do We Stand and What
Does the Future Hold?
• Current technologies and products
• Latest developments of water-based
ready-to-use SR formulations of peptides
• Alternative, non-invasive oral and transdermal formulations
• Assessing improvements to the way drugs are administered
Joel Richard, Vice President, Peptides, IPSEN Inc.
• We have designed a series of fluorescently-labeled short
peptides and have evaluated their ability to co-localize
with mitochondria. The effect of different dyes on their
biological behaviour was investigated. It was found that the
size of the fluorescent probe strongly affected the ability of
the compound to efficiently co-localize with mitochondria.
• Dansylated peptides were selected as models
9.50
Oral Peptide Drugs
• Oral peptide drugs can offer excellent advantages to
patients, physicians, and payers versus those targets and
diseases wherein ‘injectable antibodies’ is the only
available targeted therapy option.
• Two complimentary approaches will be discussed –
engineering core oral stability in peptide scaffolds
vs. using specialized formulation/delivery
approaches to protect and off-load the drug
to the desired site of action.
• Protagonist will disclose its progress towards ‘oral
peptides for IBD’ on a clinically validated target.
Dinesh V. Patel, President and CEO, Protagonist
Therapeutics Inc.
for the subsequent incorporation of
iron-chelating moieties into the backbone
sequence to provide a novel class of
mitochondria-targeted iron chelators.
Vincenzo Abbate, Research Associate,
Kings College London
2.10
Analytical Analysis to Quantify Peptides
• Utilising mass spectrometry to accurately quantify peptides
in biological matrices
• Confirming ELISA measurements or even to replace ELISA
10.30
Morning Coffee
11.00
Reviewing peptide engineering for the optimisation of drug
like properties
Peptide therapy has become a key strategy of innovative
drug development. One of the potential barriers to the use
of the native peptides in the clinic is their short half-lives.
The presentation will emphasize:
• Attributes necessary for a commercially
successful metabolic peptide
• Strategies and tactics for the design and
development of peptidase-resistant peptide
analogs and
• Strategies for half-life extension to increase
the duration of effect including formulation
tactics for patient friendly peptide delivery.
Ved Srivastava, Head, Peptide Chemistry, GSK
through mass spec
Christian Luber, Senior Scientist, Novo Nordisk
2.50
Afternoon Tea
3.20
Direct Selection of Drug-Like Macrocyclic Peptides from In
Vitro Display Libraries Built with Unnatural Amino Acids
• High affinity macrocycles are isolated by affinity to targets
of interest
• Macrocyclic peptides can adopt conformations
that promote extensive intramolecular hydrogen
bonding
11.40
12.20
Bi-Cyclic Peptides to Target Protein-Protein Interactions
• The Bicycle technology is based on repertoires of peptides
displayed on the surface of bacteriophages which can be
modified with organochemical scaffolds to create a diverse
array of constrained peptides.
• These repertoires have been extensively used for iterative
selections to identify high affinity binding peptides for a wide
array of targets, including receptors, interleukins and proteases.
• Results will be presented that exemplify the potential of the
technology and its application to animal models of diseases.
Christophe Bonny, CSO, Bicycle Therapeutics
Networking Lunch
• Cell permeability is apparent with certain
molecules
Doug Treco, President and CEO, Ra Pharma
4.00
Case Study: Advances with Linaclotide
• Reserved Speaking Slot
Mark Currie, President & CEO, Ironwood Pharmaceuticals*
4.40
Chairman’s Closing Remarks and Close of Day Two
*Subject to Final Confirmation
our registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
Supported by

4. HALF-DAY POST-CONFERENCE WORKSHOP
Wednesday 2nd July 2014
8.30am – 12.30pm
Marriott Regents Park Hotel, London, UK
Extending the
Half-Life of Peptides
Workshop Leader:
Yvonne Angell, Director of Peptide and Protein
Chemistry, IPSEN Inc.
Overview of workshop:
The major question to be asked is, can chemical
modification technologies (like PEGylation,
PASylation, hSA conjugation or even other
potential fusion technologies) be able to
compete with sustained-release (SR) formulations
which now can deliver peptides over up to 6-12
months after administration?
What would be the key advantages of peptide
conjugation vs SR formulations for half-life
extension?
Are there specific situations where conjugation
brings something that SR formulation cannot
achieve? It may include PK assessment of
peptides, comparison of PK profile for various
systems (conjugated peptides, microsphere/
implant-based systems, self-assembled peptide
formulations) and in silico potential tools such as in
vitro/in vivo correlations (IVIVC).
Agenda:
8.30
Registration and Coffee
9.00
Introdcution from Workshop Host
9.10
Simulation Exercise: Assessing conjugation
vs. SR formulation
10.30
Coffee Break
11.00
PK Assessment of Peptides
11.30
Comparing the PK Profile of various
systems
12.00
Open Discussion
12.30
End of Workshop
About the workshop host:
Yvonne M. Angell, Ph.D.
Yvonne earned her B.S. in Pharmacy
and Ph.D. in Medicinal Chemistry
degrees at the University of WisconsinMadison, U.S.A. She completed her
post-doctoral work at the University of
Minnesota, U.S.A.
Yvonne has over 15 years experience in the
pharmaceutical industry. Past experience
includes designing novel, constrained peptide
libraries to inhibit protein-protein interactions as a
scientist at Eli Lilly and Co., design and
development of bead-based binding assays to
identify new hits aimed at inhibiting proteinprotein interactions at Genetics Institute (acquired
by Wyeth in 1996, then purchased by Pfizer in
2009), and PEGylation process development
optimization of Omontys (peginesatide), which
received FDA approval in 2012, as a senior
scientist at Affymax. Her current work as Director
of Chemistry at Ipsen is focused on discovery,
design and engineering of novel, potent, selective
lead peptide and peptide chimeric compounds
for oncology, endocrinology and neurology
targets. She leads project teams as well as a
synthetic chemistry group, and has successfully
navigated
projects
from
discovery
to
development.

5. SMI'S PHARMACEUTICAL
PORTFOLIO 2014
MARCH
Controlled Release
12 – 13 March 2014, London
Adaptive Designs
24 – 25 March 2014, London
Paediatric Clinical Trials
31 – 1 April 2014, London
Pre-Filled Syringes USA
31 March – 1 April 2014, USA
APRIL
Asthma & COPD
2 – 3 April 2014, London
Biosimilars USA
7 – 8 April 2014, USA
MAY
Big Data in Pharma
12 – 13 May 2014, London
Pain Therapeutics
19 – 20 May 2014, London
ADC Summit
19 – 20 May 2014, London
Clinical Trial Logistics
21 – 22 May 2014, London
JUNE
Biobanking
23 – 24 June 2014, London
ADMET
30 June – 1 July 2014, London
Peptides
30 June – 1 July 2014, London
JULY
Lyophilisation
7 – 8 July 2014, London
BioNetworks
7 – 8 July 2014, London
Allergies
9 – 10 July 2014, London
Immunogenicity
14 – 15 July 2014, London
SPONSORSHIP AND EXHIBITION
OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising
and branding packages, uniquely tailored to
complement your company’s marketing
strategy. Prime networking opportunities exist to
entertain, enhance and expand your client
base within the context of an independent
discussion specific to your industry.
Should you wish to join the increasing number
of companies benefiting from sponsoring our
conferences please call: Alia Malick on
+44 (0) 20 7827 6168 or
email: amalick@smi-online.co.uk

6. PEPTIDES
Conference: Monday 30th June and Tuesday 1st July 2014, Marriott Regents Park Hotel, London, UK
Workshop: Wednesday 2nd July 2014, London
4 WAYS TO REGISTER
www.peptidesevent.com
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd, 2nd Floor
South, Harling House, 47-51 Great Suffolk Street, London, SE1 0BS, UK
EARLY BIRD □
DISCOUNT □
Book by 31st March to receive £300 off the conference price
Book by 30th April to receive £100 off the conference price
CONFERENCE PRICES
Unique Reference Number
I would like to attend: (Please tick as appropriate)
Fee
Total
□ Conference & Workshop
£2098.00 + VAT
£2517.60
DELEGATE DETAILS
□ Conference only
£1499.00 + VAT
£1798.80
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
□ Workshop only
£599.00
+ VAT
£718.80
£999.00
+ VAT
£1198.80
Our Reference
Title:
LVP-107
Forename:
Surname:
PROMOTIONAL LITERATURE DISTRIBUTION
Job Title:
□ Distribution of your company’s promotional
Department/Division:
literature to all conference attendees
Company/Organisation:
Email:
The conference fee includes refreshments, lunch, conference papers and access
Company VAT Number:
to the Document Portal containing all of the presentations.
Address:
LIVE STREAMING/ON DEMAND/ DOCUMENTATION
Town/City:
Post/Zip Code:
Country:
Direct Tel:
Direct Fax:
Unable to travel, but would like to watch the conference live, ask questions,
participate as if you were in the room.
Price
Total
□ Live Streaming
□ On demand
Mobile:
Switchboard:
£999.00 + VAT (UK) £1198.80
£599.00 + VAT (UK) £718.80
(available 24 hours after the event)
Signature:
Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
on the Document Portal
£499.00 + VAT
£499.00 (or only £300 if ordered with the Document Portal)
ACCOUNTS DEPT
Title:
□ Access to the conference documentation
□ The Conference Presentations - paper copy
Forename:
Surname:
Email:
£598.80
£499.00
PAYMENT
Address (if different from above):
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-107 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment
are below. Please indicate method of payment:
Town/City:
Post/Zip Code:
Country:
Direct Tel:
Direct Fax:
VENUE Marriott Hotel Regents Park, 128 King Henry's Road, London, NW3 3ST
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: hotels@smi-online.co.uk or fax +44 (0) 870 9090 712
Terms and Conditions of Booking
Payment: If payment is not made at the time of booking, then an invoice will be issued and must be
paid immediately and prior to the start of the event. If payment has not been received then credit
card details will be requested and payment taken before entry to the event. Bookings within 7 days
of event require payment on booking. Access to the Document Portal will not be given until payment
has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send a
substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing
that cancellation is made in writing and received at least 28 days prior to the start of the event.
Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or the Document Portal as these are reproduced specifically to order. If we have
to cancel the event for any reason, then we will make a full refund immediately, but disclaim any
further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection
Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other
products and services. Unless you tick here □ we may also share your data with third parties offering
complementary products or services. If you have any queries or want to update any of the data that
we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit
our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the
attached letter.
□ UK BACS
□ Wire Transfer
□ Cheque
□ Credit Card
Sort Code 300009, Account 00936418
Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
We can only accept Sterling cheques drawn on a UK bank.
□ Visa □ MasterCard □ American Express
All credit card payments will be subject to standard credit card charges.
□□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Card No:
Cardholder’s Name:
Signature:
Date:
I agree to be bound by SMi's Terms and Conditions of Booking.
Card Billing Address (If different from above):
VAT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on live
Streaming, on Demand, Document portal and literature distribution for all UK customers and
for those EU Customers not supplying a registration number for their own country here.
______________________________________________________________________________________________
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk